Canaccord Genuity Group Reaffirms Buy Rating for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Friday, Benzinga reports. They presently have a $20.00 price target on the medical instruments supplier’s stock. Canaccord Genuity Group’s target price points to a potential upside of 73.61% from the stock’s current price.

ANGO has been the topic of a number of other research reports. HC Wainwright increased their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics Stock Up 2.6%

NASDAQ:ANGO traded up $0.29 during mid-day trading on Friday, reaching $11.52. 2,156,060 shares of the company were exchanged, compared to its average volume of 506,617. AngioDynamics has a 12 month low of $9.39 and a 12 month high of $16.29. The company has a fifty day moving average of $15.39 and a 200 day moving average of $13.11. The stock has a market cap of $484.42 million, a PE ratio of -13.24 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities research analysts anticipate that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insider Activity

In other news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.00% of the company’s stock.

Institutional Trading of AngioDynamics

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $49,480,000. Armistice Capital LLC raised its position in shares of AngioDynamics by 3.9% in the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock valued at $21,828,000 after acquiring an additional 64,000 shares during the period. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $17,649,392. Bastion Asset Management Inc. raised its position in shares of AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after acquiring an additional 194,822 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of AngioDynamics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock valued at $10,786,000 after acquiring an additional 32,476 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Key AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.